Maureen McGarvey

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Gregory L. Beatty, Mark H. O’Hara, Simon F. Lacey et al. · Gastroenterology · 2018 · 500 citations · Full text

Medicine, Immunology, Oncology +12

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers

Andrew R. Haas, János L. Tanyi, Mark H. O’Hara et al. · Molecular Therapy · 2019 · 371 citations · Full text

Life Sciences, Immunology, Oncology +17

Safety and antitumor activity of chimeric antigen receptor modified T cells in patients with chemotherapy refractory metastatic pancreatic cancer.

Gregory L. Beatty, Mark H. O’Hara, Anne Marie Nelson et al. · Journal of Clinical Oncology · 2015 · 53 citations

Life Sciences, Immunology, Oncology +17

Abstract CT105: Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers

János L. Tanyi, Andrew R. Haas, Gregory L. Beatty et al. · Cancer Research · 2015 · 22 citations

Life Sciences, Immunology, Oncology +17